After five years of domestic approval, the MSD super antibiotic "Zerbaxa (Ceftolozane/Tazobactam)" was registered. It is expected to help reduce the recent surge in carbapenem antibiotic resistance.

MSD Korea held a press conference at the Koreana Hotel in Jung-gu, Seoul on the 27th to commemorate the registration of Zerbaxa, a multidrug-resistant antifungal antibiotic. Zerbaxa is a combination of new cephalosporin-based antibiotics Ceftolozane and beta-lactam degrading enzyme inhibitors Tazobactam. In response to the main resistance mechanism of pseudomonas aeruginosa, it has proven its activity in multidrug-resistant pseudomonas aeruginosa and ESBL-producing intestinal bacteria. ESCMID and IDSA recommend